Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBC-129 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
NCT05701527Phase 1Recruiting
- Sponsor
- Experimental Drug Development Centre
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of EBC-129 in solid tumor (advanced stage) (8 arms), sponsored by Experimental Drug Development Centre. Primary endpoints: Number of patients with serious adverse events and treatment emergent adverse events at 2 years, Maximum tolerated dose at 2 years and 2 more. Started Apr 2023; status: recruiting.
02
Drugs
EBC-129
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05701527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701527.